KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Cash & Equivalents: 2009-2025

Historic Revenue - Interest and Investment Income for Novavax (NVAX) over the last 2 years, with Mar 2011 value amounting to $70.1 million.

  • Novavax's Cash & Equivalents fell 53.28% to $268.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $268.0 million, marking a year-over-year decrease of 53.28%. This contributed to the annual value of $530.2 million for FY2024, which is 6.73% down from last year.
  • Novavax's Cash & Equivalents amounted to $268.0 million in Q3 2025, which was up 5.63% from $253.7 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Cash & Equivalents ranged from a high of $2.1 billion in Q2 2021 and a low of $253.7 million during Q2 2025.
  • For the 3-year period, Novavax's Cash & Equivalents averaged around $490.9 million, with its median value being $530.2 million (2024).
  • Within the past 5 years, the most significant YoY rise in Novavax's Revenue - Interest and Investment Income was 10.91% (2010), while the steepest drop was 12.57% (2010).
  • Over the past 3 years, Novavax's Revenue - Interest and Investment Income (Quarterly) stood at $85.6 million in 2009, then dropped by 12.57% to $74.8 million in 2010, then dropped by 6.95% to $70.1 million in 2011.
  • Its last three reported values are $268.0 million in Q3 2025, $253.7 million for Q2 2025, and $263.3 million during Q1 2025.